MIAMI, Aug. 26, 2020 (GLOBE NEWSWIRE) -- Ehave, Inc., (OTC Pink: EHVVF) (the “Company”), a provider of digital therapeutics delivering evidence-based therapeutic interventions to healthcare patients, announced today the release of Doctors Dictation, an artificial intelligence (AI) powered video and voice analysis module, as part of the Ehave Dashboard. Ehave Doctors Dictation is an AI powered video and voice analysis module that combines text, audio, and video with our automated analysis of media for a beautiful new way to manage and understand your information. Doctors or practitioners can spend more time speaking to their patients instead of focusing on taking notes. Doctors can then go back and review details for efficient and effective diagnosis of patients. This function can even extend to prescribing medicine. Researchers and clinicians can use this technology to effective and efficient research their trial and organize all their data in one place with this module.
A 2017 study by the Wisconsin Medical School found doctors spend almost half of their time entering data in computers. Obviously, this time would be better utilized seeing patients. Not only is entering data time consuming, it is also prone to errors. According to Fortune.com, the healthcare industry still sees more than 12 million “serious diagnostic errors” every year. In 2016 NPR reported that a team of researchers found voice recognition software makes 20% fewer errors than human typists. No matter how hard they try, most typists of medical records clock in around 40 words per minute. The real promise of health care AI is to enhance the work of physicians and other members of the care team, not to replace them.
With Ehave Doctors Dictation, each result, or detection, is paired with a timestamp, so physicians and their staff can easily create a digital record. Once this digital record is created, it can be used for detailed video and audio search. The physician and his or her staff can also navigate quickly to an interesting part of the video or audio for further analysis. For objects, faces, text, and people, Ehaves’ Doctors Dictation also returns bounding box coordinates, which is the specific location of the detection in the frame. Ehave Doctors Dictation can also monitor a live stream to detect and search for phrases from search data that you provide. You can incorporate audio analysis such as closed captioning, keyword, emotion detection and more. Ehave is slated to include this technology in its upcoming release of Ehave Dash.
“The applications of AI to assist physicians with their practice seems more pragmatic and expansive than those that attempt to replace existing health care services,” said Ehave, Inc. CEO, Ben Kaplan. Mr. Kaplan continued, “We see a tremendous opportunity for AI to be a solution for physicians, rather than a replacement. I believe the ones who will benefit most from AI will be the patients. This is why I am so excited about Doctors Dictation and our Ehave Dashboard. Better care for patients."
Ehave, Inc. (EHVVF) is a provider of digital therapeutics delivering evidence-based therapeutic interventions to patients. Our primary focus is on improving the standard care in therapeutics to prevent or treat brain disorders or diseases through the use of digital therapeutics, independently or together, with medications, devices, and other therapies to optimize patient care and health outcomes. Our main product is the Ehave Telemetry Portal, which is a mental health informatics platform that allows clinicians to make objective and intelligent decisions through data insights. The Ehave Infinity Portal offers a powerful machine learning and artificial intelligence platform with a growing set of advanced tools and applications developed by Ehave and its leading partners. This empowers patients, healthcare providers, and payers to address a wide range of conditions through high quality, safe, and effective data-driven involvement with intelligent and accessible tools. For more information visit: www.ehave.com.
Forward-Looking Statement Disclaimer
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward-looking statements are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements: (i) the initiation, timing, progress and results of the Company’s research, manufacturing and other development efforts; (ii) the Company’s ability to advance its products to successfully complete development and commercialization; (iii) the manufacturing, development, commercialization, and market acceptance of the Company’s products; (iv) the lack of sufficient funding to finance the product development and business operations; (v) competitive companies and technologies within the Company’s industry and introduction of competing products; (vi) the Company’s ability to establish and maintain corporate collaborations; (vii) loss of key management personnel; (viii) the scope of protection the Company is able to establish and maintain for intellectual property rights covering its products and its ability to operate its business without infringing the intellectual property rights of others; (ix) potential failure to comply with applicable health information privacy and security laws and other state and federal privacy and security laws; and (x) the difficulty of predicting actions of the USA FDA and its regulations. All forward-looking statements included in this press release are made only as of the date of this press release. The Company assumes no obligation to update any written or oral forward-looking statement unless required by law. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is contained under the heading "Risk Factors" in Ehave, Inc.’s Registration Statement on Form F-1 filed with the Securities and Exchange Commission (SEC) on September 24, 2015, as amended, which is available on the SEC's website, http://www.sec.gov.
For Investor Relations, please contact:
Gabe Rodriguez
Phone: (623) 261-9046
Email: erelationsgroup@gmail.com